Abhi Vase
Chief Commercial Officer
Healthcare executive with 20 years of experience and multiple startup exits to Medtronic, St. Jude Medical and Abbott in cardiology, metabolic and neurology.
ViewMind is the global leader in precision measurement of ocular movement alterations, a window into brain health. With high sensitivity and specificity, ViewMind’s digital assessments can contribute to advancing precision drug development and precision patient care.
individuals suffer from neurological
disorders, with dementia being the world’s 7th most frequent cause of death.
Source: WHO
leading global cause of disability is mental health problems. Brain health is the foundation of our mental health.
Source: WHO
FDA final marketing approval rate for central nervous system (CNS) drugs, compared to 13.3% for non-CNS drugs.
Source: NIH
“ViewMind’s technology applies to a range of neurocognitive conditions, an exceptional and unique value proposition. ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology.
The company’s offering spans the diagnostic continuum, from early stage to disease progression, monitoring, response, and treatment.”
Our brain is good at hiding symptoms thanks to cognitive reserve. By the time a disorder is detected, it is often too late to intervene. Existing solutions – biomarkers or neuroimaging – are expensive and invasive, and their use is limited to patients already presenting symptoms. Another challenge is understanding the cognitive and functional impact of physiological and metabolic changes on the brain.
ViewMind is developing a solution to change the course of central nervous system drug development and precision patient care.
ViewMind measures neurocognitive health by cognitive domain and the corresponding brain regions.
An assessment is conducted using a head-mounted display (HMD). During the assessment, sensors track eye movements in response to visual stimuli.
Patented ocular digital phenotyping employs advanced statistical models to analyze data from numerous permutations. It can measure minor cognitive alterations or changes to high-level motor function.
ViewMind generates a report that provides insights into the patient’s cognitive condition through analysis of the data collected. This report is then accessible to the physician.
Over 25 year experience with tier 1 media companies, including 15 years as CEO. Chair person of UNICEF Brazil.
Business development executive with a neurology, psychiatry and mental health focus.
Founder and Managing Partner of R3i Ventures, a seed-stage VC Fund based in Luxembourg, Singapore and Silicon Valley.
Founder and managing partner of CITES, a deeptech early stage VC fund.
Professor, Director and founder of the Antioquia Neuroscience Group at the University of Antioquia in Medellín, Colombia. Dr. Lopera is one of the world’s leading specialists on Alzheimer’s & neurodegenerative disorders.
Dr. Greenleaf is a Stanford University research neuroscientist and medical product developer and one the world’s leading authorities in the use of virtual reality technology in healthcare.
A pharmaceutical executive with over 20 years of experience in global medical roles, including Novo Nordisk, AstraZeneca and Zealand Pharma.
Brain Health for Life
Easy to perform. Non-invasive.
Precision Neurology.